Clinical Trial Update: High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing high-dose versus standard-dose daunorubicin for induction treatment of acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Daunorubicin (daunorubicin)

Snippet

Sponsor: Cooperative Study Group A for Hematology | Conditions: ACUTE MYELOGENOUS LEUKEMIA | Phase 3 | Status: COMPLETED